Read + Share
Jimenez-Vicente C, Beneit P, Cano-Ferri I, Merchan B, et al. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study
of the early-access program in Spain. Ann Hematol 2025;104:4863-4871.
PMID: 40650712
|
 |
|
Jimenez-Vicente C, Beneit P, Cano-Ferri I, Merchan B, et al. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study
of the early-access program in Spain. Ann Hematol 2025;104:4863-4871.
PMID: 40650712
|
|
|
|